Via Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
There's a lot of excitement around the new insights that vulnerable plaque, a certain kind of inflammatory plaque, is the culprit in myocardial infarction, but so far, no one has figured out how to treat it. Thomas Quertermous of Stanford has identified inflammatory pathways that contribute to atherosclerosis and Via Pharmaceuticals was formed to develop a drug, already tested extensively in humans, that emanated from his research program.